Geron Corporation (GERN) Research

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Market snapshot

Symbol
GERN
Price
$1.26
Day change
+2.44%
Market cap
$808.3M
P/E ratio
-12.12x
52-week range
1.04-2.01
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.89

Peer companies

  • Arvinas, Inc. (ARVN)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Day One Biopharmaceuticals, Inc. (DAWN)
  • LENZ Therapeutics, Inc. (LENZ)
  • Replimune Group, Inc. (REPL)
  • Rezolute, Inc. (RZLT)
  • Savara Inc. (SVRA)
  • Tyra Biosciences, Inc. (TYRA)

Recent insider activity

  • Spiegel Robert J. — A-Award (220000 shares) on 2026-05-20
  • O'Farrell Elizabeth G. — A-Award (220000 shares) on 2026-05-20
  • Molineaux Susan — A-Award (220000 shares) on 2026-05-20
  • McDonald John F — A-Award (220000 shares) on 2026-05-20
  • Bir Dawn Carter — A-Award (220000 shares) on 2026-05-20

Open Geron Corporation (GERN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.